Dapagliflozin versus empagliflozin in patients with chronic kidney disease

• Hoofdauteurs: Hilmi Alnsasra (Auteur), Gal Tsaban (Auteur), Adam Solomon (Auteur), Fouad Khalil (Auteur), Enis Aboalhasan (Auteur), Abed N. Azab (Auteur), Joseph Azuri (Auteur), Ariel Hammerman (Auteur), Ronen Arbel (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished. We examined the cost-per-outcome implications of util...